Comparative Pharmacology
Head-to-head clinical analysis: SULFAMETHOXAZOLE versus SULFISOXAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAMETHOXAZOLE versus SULFISOXAZOLE.
SULFAMETHOXAZOLE vs SULFISOXAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Displaces dihydropteroate synthetase from its substrate para-aminobenzoic acid (PABA), inhibiting bacterial folate synthesis. Bacteriostatic against susceptible organisms.
Sulfisoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the synthesis of dihydrofolic acid and ultimately inhibiting bacterial folate synthesis and DNA replication.
800 mg sulfamethoxazole with 160 mg trimethoprim (DS tablet) orally every 12 hours.
1-2 g orally once, then 500 mg-1 g orally every 4-6 hours; maximum 6 g/day.
MODERATE Risk
MODERATE Risk
9-11 hours in adults with normal renal function. Prolonged in renal impairment: up to 20-30 hours. In neonates, 6-12 hours.
Clinical Note
moderateSulfisoxazole + Gatifloxacin
"Sulfisoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfamethoxazole + Gatifloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfisoxazole + Rosoxacin
"Sulfisoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfamethoxazole + Rosoxacin
Terminal elimination half-life is 5-7 hours in adults with normal renal function; prolonged to 12-20 hours in renal impairment (CrCl <30 mL/min).
Primarily renal; ~80-90% excreted unchanged in urine, with 15-30% as acetylated metabolite. Biliary/fecal <5%.
Renal excretion accounts for 70-85% of elimination, predominantly as unchanged drug (30-50%) and the N4-acetyl metabolite (15-30%). Biliary/fecal excretion is minimal (<5%).
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
"Sulfamethoxazole may increase the hypoglycemic activities of Rosoxacin."